|
|
No. of Patients
(% of total cohort)
|
No. of Patients
(% of total cohort)
|
1
|
Antihistamine regular dose
|
153
(61.2%)
|
10
(41.7%)
|
|
Antihistamine high dose
|
7
(2.8%)
|
2
(8.3%)
|
|
Steroids course
|
1
(0.4%)
|
0
|
|
Montelukast only
|
0
|
1
(4.2%)
|
|
Total
|
161
(64.4%)
|
13
(54.2%)
|
2
|
Antihistamine regular dose + Steroids
|
32
(12.8%)
|
2
(8.3%)
|
|
Antihistamine high dose + Steroids
|
9
(3.6%)
|
0
|
|
Antihistamine regular dose + Montelukast
|
2
(0.8%)
|
0
|
|
Antihistamine high dose + Montelukast
|
3
(1.2%)
|
2
(8.3%)
|
|
Montelukast + Omalizumab
|
0
|
1
(4.2%)
|
|
Total
|
46
(18.4%)
|
5
(20.8%)
|
3
|
Antihistamine high dose + Steroids + Montelukast
|
5
(2%)
|
0
|
|
Antihistamine high dose + steroids + Omalizumab
|
1
(0.4%)
|
0
|
|
Total
|
6
(2.4%)
|
0
|
4
|
Antihistamine high dose + Steroids + Montelukast + Omalizumab
|
0
|
2
(8.3%)
|
No record of medications
|
No record of medications
|
37
(14.8%)
|
4
(16.7%)
|
Total of patients |
Total of patients |
250 |
24 |